Top
Main

All outcomes

Feedback
Home
Show Outline
Top   Main   All Outcomes
Home   COVID-19 treatment studies for Metformin  COVID-19 treatment studies for Metformin  C19 studies: Metformin  Metformin   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
Loading...
Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc
Supplementary Data — Metformin for COVID-19: real-time meta analysis of 40 studies
Covid Analysis, July 6, 2022, DRAFT
https://c19early.com/mfmeta.html
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Reis (DB RCT) 27% 0.73 [0.28-1.94] death 7/215 9/203 Improvement, RR [CI] Treatment Control Reis (DB RCT) 6% 0.94 [0.55-1.61] hosp. 24/215 24/203 Reis (DB RCT) 39% 0.61 [0.26-1.41] hosp. 8/168 14/179 Reis (DB RCT) -14% 1.14 [0.73-1.81] hosp./ER 34/215 28/203 Reis (DB RCT) 12% 0.88 [0.45-1.71] hosp./ER 14/168 17/179 Reis (DB RCT) 31% 0.69 [0.28-1.68] progression 8/216 11/205 Reis (DB RCT) 26% 0.74 [0.29-1.90] progression 7/171 10/181 Reis (DB RCT) 1% 0.99 [0.88-1.11] viral+ 215 (n) 203 (n) Hunt 67% 0.33 [0.25-0.43] death 73/3,956 1,539/22,552 Tamura 97% 0.03 [0.00-0.58] death 115 (n) 73 (n) Luo 75% 0.25 [0.07-0.84] death 3/104 22/179 Wang 58% 0.42 [0.01-1.98] death 1/9 13/49 Chen 33% 0.67 [0.20-1.78] death 4/43 15/77 Kim 64% 0.36 [0.10-1.23] death 113 (n) 122 (n) Kim 52% 0.48 [0.19-1.24] progression 113 (n) 122 (n) Li 78% 0.22 [0.09-0.54] death 2/37 21/94 Li -27% 1.27 [0.12-13.6] ventilation 1/37 2/94 Goodall 3% 0.97 [0.75-1.25] death 74/210 280/771 Gao -225% 3.25 [1.03-7.41] progression 16/56 4/54 Pérez-Belm.. (PSM) -10% 1.10 [0.84-1.40] death 79/249 79/249 Bramante 7% 0.93 [0.81-1.06] death 394/2,333 791/3,923 Bramante 24% 0.76 [0.60-0.96] death 1,129 (n) 2,173 (n) Bramante -3% 1.03 [0.84-1.27] death 1,204 (n) 1,750 (n) Lalau (PSM) 22% 0.78 [0.55-1.10] death 671 (n) 419 (n) Lalau (PSM) 18% 0.82 [0.61-1.11] death/int. 671 (n) 419 (n) Lalau (PSM) 7% 0.93 [0.64-1.35] ventilation 671 (n) 419 (n) Huh -1% 1.01 [0.75-1.37] progression 104/272 774/2,533 Huh 4% 0.96 [0.82-1.12] cases population-based cohort Crouse 61% 0.39 [0.16-0.87] death 8/76 34/144 Lally 52% 0.48 [0.28-0.84] death 16/127 144/648 Oh -26% 1.26 [0.81-1.95] death 5,946 (n) 5,946 (n) Oh (PSM) 28% 0.72 [0.63-0.81] cases 390/5,946 541/5,946 Wargny 28% 0.72 [0.53-0.95] death 247/1,553 330/1,241 Wargny 15% 0.85 [0.74-0.97] no disch. 690/1,553 702/1,241 Holt -27% 1.27 [0.72-2.22] cases 12/429 434/14,798 Khunti 23% 0.77 [0.73-0.81] death population-based cohort Jiang (PSM) 46% 0.54 [0.13-2.26] death 3/74 10/74 Jiang (PSM) 80% 0.20 [0.05-0.77] progression 8/74 17/74 Ghany 66% 0.34 [0.19-0.59] death 392 (n) 747 (n) Ghany 29% 0.71 [0.52-0.86] hosp. 392 (n) 747 (n) Ghany 68% 0.32 [0.22-0.45] ARDS 392 (n) 747 (n) Alamgir 27% 0.73 [0.63-0.84] death 11,062 (n) 11,062 (n) Alamgir 34% 0.66 [0.49-0.90] death 5,369 (n) 5,369 (n) Alamgir 30% 0.70 [0.53-0.95] death 2,525 (n) 2,525 (n) Ravindra 30% 0.70 [0.28-1.56] death 5/53 57/313 Blanc 79% 0.21 [0.03-1.46] death 1/14 25/75 Blanc -44% 1.44 [1.00-2.07] cases 11/16 78/163 Boye 10% 0.90 [0.86-0.94] hosp. 2,067/4,250 3,196/5,281 Cheng (PSM) -65% 1.65 [0.71-3.86] death 678 (n) 535 (n) Wang 12% 0.88 [0.81-0.97] ICU 6,504 (n) 10,000 (n) Ando 39% 0.61 [0.38-0.99] hosp. Wander 15% 0.85 [0.80-0.90] death Wander 2% 0.98 [0.92-1.06] ICU Wander 3% 0.97 [0.94-1.01] hosp. Saygili (PSM) 42% 0.58 [0.37-0.92] death 120 (n) 120 (n) Ong 47% 0.53 [0.31-0.87] death 33/186 57/169 Ong 24% 0.76 [0.50-1.10] death 28/109 57/169 Ong 85% 0.15 [0.04-0.55] death 2/40 57/169 Ong 76% 0.24 [0.07-0.68] death 3/37 57/169 Bliden 60% 0.40 [0.12-1.37] death 3/34 9/41 Bliden 76% 0.24 [0.06-1.03] ventilation 2/34 10/41 Al-Salameh 55% 0.45 [0.17-0.94] death/ICU 9/47 22/50 Al-Salameh -68% 1.68 [1.12-2.05] death/ICU 34/43 22/50 Wallace (PSW) 72% 0.28 [0.21-0.37] death 103/1,203 1,536/6,970 Ojeda-Ferná.. (PSM) 16% 0.84 [0.79-0.89] death 1,476/6,556 1,787/6,556 Ojeda-Ferná.. (PSM) 22% 0.78 [0.72-0.84] death 968/6,556 1,261/6,556 Ojeda-Ferná.. (PSM) 22% 0.78 [0.64-0.95] ICU 166/6,556 212/6,556 Ojeda-Ferná.. (PSM) 3% 0.97 [0.94-1.00] hosp. 3,551/6,556 3,670/6,556 Ojeda-Ferná.. (PSM) 8% 0.92 [0.84-1.00] death 793/3,297 876/3,297 Ojeda-Ferná.. (PSM) 16% 0.84 [0.75-0.94] death 512/3,297 618/3,297 Ojeda-Ferná.. (PSM) 39% 0.61 [0.44-0.82] ICU 64/3,297 102/3,297 Ojeda-Ferná.. (PSM) -2% 1.02 [0.97-1.07] hosp. 1,822/3,297 1,792/3,297 Usman 60% 0.40 [0.12-1.37] death 3/34 9/41 Usman 76% 0.24 [0.06-1.03] ventilation 2/34 10/41 Usman 34% 0.66 [0.39-1.13] hosp. time 34 (n) 41 (n) Wong 51% 0.49 [0.43-0.57] death Wong 41% 0.59 [0.52-0.66] ventilation Wong 40% 0.60 [0.57-0.63] hosp. Wong (PSW) 59% 0.41 [0.22-0.80] death 786 (n) 428 (n) Wong (PSW) 61% 0.39 [0.21-0.75] no recov. 786 (n) 428 (n) Wong (PSW) 64% 0.36 [0.18-0.76] improv. 786 (n) 428 (n) Wong (PSW) 56% 0.44 [0.24-0.81] no disch. 786 (n) 428 (n) MacFadden 1% 0.99 [0.96-1.01] cases n/a n/a metformin COVID-19 outcomes c19early.com/mf Jul 2022 Favors metformin Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit